GlassScriptPhysician profile
Brooke B Teal
NPI 1427093731
$10,629.88
in general payments reported to CMS, 2019-2025
57 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,106 · 2022: $1,972 · 2023: $2,101 · 2024: $2,795 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982 · Long Term Medical Supply Or Device Loan: $2,299 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.66 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $271.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,117.59 | 2021-2025 | |
| Pfizer INC. | $732.57 | 2021-2025 | |
| Janssen Biotech, INC. | $493.83 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $382.24 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $333.86 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $312.63 | 2021-2025 | Ojjaara, Shingrix |
| Genentech USA, INC. | $304.21 | 2021-2025 | Polivy, Tecentriq, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $303.48 | 2021-2025 | Tagrisso, Lynparza, Enhertu |
| Astellas Pharma US INC | $271.59 | 2021-2025 | Padcev |
| Seagen INC. | $261.13 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Abbvie INC. | $260.89 | 2021-2025 | |
| Incyte Corporation | $250.25 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Sobi, INC | $248.85 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $247.55 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Exelixis INC. | $217.82 | 2022-2025 | Cabometyx |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Teal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.